Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial
Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial
复制标题
DOI：
10.1136/ard.2011.153551
复制
发表时间：
2012-02-01
影响因子：
27.4
通讯作者：
Kavanaugh, Arthur
中科院分区：
文献类型：
--
作者：
Curtis, Jeffrey R.;Yang, Shuo;Kavanaugh, Arthur
目的 衍生并验证决策树，将类风湿性关节炎 (RA) 患者在开始服用依那西普联合或不联合甲氨蝶呤 12 周后分为三组：预计 1 年内达到低疾病活动度 (LDA) 的患者；预计 1 年时不会达到 LDA 的患者和需要额外治疗时间的患者进行分类。方法对参加 TEMPO 试验的 RA 患者的数据进行了分析。分类和回归树用于开发和验证决策树模型，并通过第 12 周和更早的评估来预测长期 LDA。 LDA，定义为 28 个关节的疾病活动评分 (DAS28)
Objective To derive and validate decision trees to categorise rheumatoid arthritis (RA) patients 12 weeks after starting etanercept with or without methotrexate into three groups: patients predicted to achieve low disease activity (LDA) at 1 year; patients predicted not to achieve LDA at 1 year and patients who needed additional time on therapy to be categorised.Methods Data from RA patients enrolled in the TEMPO trial were analysed. Classification and regression trees were used to develop and validate decision tree models with week 12 and earlier assessments that predicted long-term LDA. LDA, defined as disease activity score in 28 joints (DAS28)